List of Figures
Figure 1: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Asthma, 2016–2023 25
Figure 2: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for COPD, 2016–2023 26
Figure 3: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Idiopathic Pulmonary Fibrosis, 2016–2023 27
Figure 4: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Cystic Fibrosis, 2016–2023 28
Figure 5: Respiratory Disorders Therapeutics Market, Schematic Representation of Potential Clinical Courses of IPF 33
Figure 6: Respiratory Disorders Therapeutics Market, Progression of CF 35
Figure 7: Respiratory Disorders Therapeutics Market, Global, Key Marketed Products and Approved Indications, 2017 42
Figure 8: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Advair ($bn), 2006–2023 44
Figure 9: Respiratory Disorders Therapeutics Market, Advair Market Share Within Asthma, Global, 2006–2023 44
Figure 10: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Symbicort ($bn), 2006–2023 46
Figure 11: Respiratory Disorders Therapeutics Market, Symbicort Market Share Within Asthma, Global, 2006–2023 47
Figure 12: Respiratory Disorders Therapeutic Market, Global, Annual Revenue for Spiriva ($bn), 2006–2023 48
Figure 13: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Xolair ($m), 2006–2023 49
Figure 14: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Ventolin ($bn), 2006–2023 51
Figure 15: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Pulmicort ($bn), 2006–2023 52
Figure 16: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Orkambi ($bn), 2015–2023 53
Figure 17: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Relvar/Breo Ellipta ($bn), 2013–2023 55
Figure 18: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Singulair ($bn), 2006–2023 57
Figure 19: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Esbriet ($m), 2008–2023 58
Figure 20: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Kalydeco ($m), 2012–2023 60
Figure 21: Respiratory Disorders Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017 62
Figure 22: Respiratory Disorders Therapeutics Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2017 63
Figure 23: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Stage of Development, 2017 64
Figure 24: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Molecule Type, 2017 65
Figure 25: Respiratory Disorders Therapeutics Market, Global, Pipeline by Molecular Targets and Stage of Development, 2017 66
Figure 26: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Molecular Targets, 2017 67
Figure 27: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2017 68
Figure 28: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2017 69
Figure 29: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2017 70
Figure 30: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2017 71
Figure 31: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2017 72
Figure 32: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2017 73
Figure 33: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2017 74
Figure 34: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2017 75
Figure 35: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development, 2006–2017 76
Figure 36: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication, 2006–2017 77
Figure 37: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type, 2006–2017 78
Figure 38: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target, 2006–2017 79
Figure 39: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development, 2006–2017 80
Figure 40: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication, 2006–2017 81
Figure 41: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type, 2006–2017 82
Figure 42: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target, 2006–2017 83
Figure 43: Respiratory Disorders Therapeutics Market, Global, Revenue for Ivacaftor/Tezacaftor ($bn), 2018–2023 84
Figure 44: Respiratory Disorders Therapeutics Market, Global, Revenue for (Fluticasone Furoate plus Umeclidinium Bromide plus Vilanterol Trifenatate) ($m), 2017–2023 85
Figure 45: Respiratory Disorders Therapeutics Market, Global, Revenue for Dupixent ($m), 2017–2023 86
Figure 46: Respiratory Disorders Therapeutics Market, Global, Revenue for Benralizumab ($m), 2017–2023 88
Figure 47: Respiratory Disorders Therapeutics Market, Global, Revenue for Tralokinumab ($m), 2017–2023 89
Figure 48: Respiratory Disorders Therapeutics Market, Global, Revenue for PT010 ($m), 2017–2023 90
Figure 49: Respiratory Disorders Therapeutics Market, Global, Market Size ($bn), 2016–2023 92
Figure 50: Respiratory Disorders Therapeutics Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2016–2023 95
Figure 51: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for G Protein-Coupled Receptor Modulators ($bn), 2016–2023 97
Figure 52: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Immune/Inflammatory System Targets ($bn), 2016–2023 98
Figure 53: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Transcription Factor Therapies ($bn), 2016–2023 99
Figure 54: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Signal Transduction Modulators ($bn), 2016–2023 100
Figure 55: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for CFTR Modulators ($bn), 2016–2023 101
Figure 56: Respiratory Disorders Therapeutics Market, Global, Company Analysis Matrix, 2016–2023 102
Figure 57: Respiratory Disorders Therapeutics Market, Global, Cluster Graph by Growth and Market Share, 2016–2023 103
Figure 58: Respiratory Disorders Therapeutics Market, Global, Forecast Revenue by Company, 2016–2023 105
Figure 59: Respiratory Disorders Therapeutics Market, Global, Forecast Market Share by Company (%), 2016–2023 106
Figure 60: Respiratory Disorders Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2016–2023 107
Figure 61: Respiratory Disorders Therapeutics Market, Global, Revenue by Product Type, 2016–2023 108
Figure 62: Respiratory Disorders Therapeutics Market, Global, GlaxoSmithKline Annual Revenue Forecast ($bn), 2016–2023 109
Figure 63: Respiratory Disorders Therapeutics Market, Global, Vertex Annual Revenue Forecast ($bn), 2016–2023 110
Figure 64: Respiratory Disorders Therapeutics Market, Global, AstraZeneca Annual Revenue Forecast ($bn), 2016–2023 111
Figure 65: Respiratory Disorders Therapeutics Market, Global, Roche Annual Revenue Forecast ($bn), 2016–2023 113
Figure 66: Respiratory Disorders Therapeutics Market, Global, Boehringer Ingelheim Annual Revenue Forecast ($bn), 2016–2023 114
Figure 67: Respiratory Disorders Therapeutics Market, Global, Novartis Annual Revenue Forecast ($m), 2016–2023 115
Figure 68: Respiratory Disorders Therapeutics Market, Global, Teva Annual Revenue Forecast ($bn), 2016–2023 116
Figure 69: Respiratory Disorders Therapeutics Market, Global, Sumitomo Dainippon Annual Revenue Forecast ($bn), 2016–2023 117
Figure 70: Respiratory Disorders Therapeutics Market, Global, Regeneron Annual Revenue Forecast ($bn), 2016–2023 117
Figure 71: Respiratory Disorders Therapeutics Market, Global, Merck & Co. Annual Revenue Forecast ($bn), 2016–2023 118
Figure 72: Respiratory Disorders Therapeutics Market, Global, Companies by Type, 2017 119
Figure 73: Respiratory Disorders Therapeutics Market, Global, High-Activity and Late-Stage Developers by Level of Respiratory Specialization, 2017 120
Figure 74: Respiratory Disorders Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Respiratory Disorders, 2016–2023 121
Figure 75: Respiratory Disorders Therapeutics Market, Global, Licensing Deals by Region, Year and Value, 2006–2017 122
Figure 76: Respiratory Disorders Therapeutics Market, Global, Licensing Deal Volume and Value by Indication, 2006–2017 123
Figure 77: Respiratory Disorders Therapeutics Market, Global, Licensing Deal Volume and Value by Stage of Development, 2006–2017 124
Figure 78: Respiratory Disorders Therapeutics Market, Global, Licensing Deals by Molecule Type and Target, 2006–2017 125
Figure 79: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Region, Year and Value, 2006–2017 133
Figure 80: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Indication, 2006–2017 133
Figure 81: Respiratory Disorders Therapeutics Market, Global, Co-development Deal Volume and Value by Stage of Development, 2006–2017 134
Figure 82: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Molecule Type and Target, 2006–2017 135
Figure 83: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Discovery, 2017 147
Figure 84: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Preclinical, 2017 148
Figure 85: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, IND/CTA-Filed/Phase 0, 2017 149
Figure 86: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase I, 2017 149
Figure 87: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase II, 2017 150
Figure 88: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase III, 2017 151
Figure 89: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Pre-registration, 2017 151